Myotrophin in human heart failure
Russell J. O'Brien, MRCP*,
Ian Loke, MRCP*,
Joan E. Davies, PhD, FRCP*,
Iain B. Squire, MD, FRCP* and
Leong L. Ng, MD, FRCP*,*
* Department of Medicine and Therapeutics, University of Leicester, Leicester Royal Infirmary, Leicester, United Kingdom
View larger version (15K):
[in a new window]
|
Figure 1 A standard curve for the myotrophin competitive immunoassay. A patient's plasma extract (solid circles joined by dotted line) was diluted in twofold steps, showing parallelism with the standard curve.
|
|
View larger version (35K):
[in a new window]
|
Figure 2 A Western blot of rat tissue extracts (50 µg per lane) resolved on 15% SDS-polyacrylamide gels, using the antibody (1 µg/ml) to detect myotrophin. A 12 kD band was evident in all extracts, with the lowest levels in spleen.
|
|
View larger version (17K):
[in a new window]
|
Figure 3 Size exclusion chromatography with analysis of the fractions for myotrophin. The points of elution of markers for 20 kD and 6.5 kD are indicated by arrows. Two peaks of immunoreactivity for myotrophin are evident at 12 and 2.7 kD.
|
|
View larger version (27K):
[in a new window]
|
Figure 4 Box plot of log-transformed plasma myotrophin levels in normal subjects and HF patients of both genders. Hatched bars = male; open bars = female.
|
|
View larger version (29K):
[in a new window]
|
Figure 5 Relationship of plasma myotrophin with severity of heart failure in males and females. Hatched bars = male; open bars = female. NYHA = New York Heart Association.
|
|
|
